Search Results

You are looking at 111 - 120 of 848 items for :

  • Refine by Access: All x
Clear All
Full access

Defining and Managing High-Risk Multiple Myeloma: Current Concepts

Luciano J. Costa and Saad Z. Usmani

7 molecular subgroups of NDMM, 9 3 of which were described as having the highest risk of early relapse: the MMSET gene overexpression, MAF / MAFB overexpression, and proliferative gene overexpression subgroups. The Arkansas group also developed

Full access

Use of Biomarkers and Multigene Assays in Breast Cancer

Lee S. Schwartzberg

, they can stratify patients into lower and higher risk of later relapse between years 5 through 10 after diagnosis. The Breast Cancer Index also appears to have some predictive value for prolonged endocrine therapy. As a fundamental change, the latest

Full access

Analysis of Circulating Tumor Cells in Breast Cancer

Zeynep Eroglu, Odicie Fielder, and George Somlo

Through coordinated scientific, medical, and public health advances, 5-year survival rates for breast cancer approach 90%. However, microscopic residual disease frequently results in local relapse or metastasis, leading to approximately 40

Full access

Novel Targets for Therapeutic Agents in Small Cell Lung Cancer

Patrick C. Ma and Ravi Salgia

. N901-blocked ricin for relapsed small-cell lung cancer . Chest 1993 ; 103 : 436S – 439S . 60 Lynch TJ Jr Lambert JM Coral F . Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin . J Clin Oncol 1997

Full access

Optimizing Endocrine Therapy for Breast Cancer

Amelia B. Zelnak and Ruth M. O'Regan

improved outcomes for patients with all stages of hormone receptor (HR)–positive breast cancer. However, despite the marked success of endocrine therapy in the treatment of HR-positive breast cancers, many patients will experience relapse and all patients

Full access

Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of Randomized Controlled Trials

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza

investigators pooled estimates for distant metastases, visceral recurrences, and occurrence rate of locoregional relapses. Considering that treatment outcomes may vary among different types of bisphosphonates, the investigators performed subgroup analyses for

Full access

Systemic Therapy for Small Cell Lung Cancer

Benjamin Levy, Ashish Saxena, and Bryan J. Schneider

inevitably experience disease relapse and die. Unfortunately, scientific research has yielded few advances over the past 30 years, resulting in a dismal median survival time for ES-SCLC of 8 to 10 months. However, renewed interest has been shown in

Full access

Thymoma Complicated by Acquired Amegakaryocytic Thrombocytopenia and Pure Red Cell Aplasia

Carl M. Gay, William N. William Jr, Sa A. Wang, and Thein Hlaing Oo

discontinued in September 2011. Two months later, his Hb level and platelet count decreased again. Bone marrow biopsy showed relapsed PRCA and AAMT. He was then restarted on cyclosporine, 300 mg/d, and his Hb level and platelet count subsequently increased

Full access

Anaplastic Classic Kaposi Sarcoma: PD-L1 Expression and Response to Immunotherapy: A Case Report and Review of the Literature

Ivan Lolli, Anna Maria Valentini, Angela Dalia Ricci, and Raffaele Armentano

aggressiveness led to transfemoral amputation of the left leg and a lung metastasectomy. Further amputation at a higher level was proposed at the subsequent relapse at the left stump level. The choice of immunotherapy with pembrolizumab as an “extrema ratio

Full access

NCCN Task Force Report: Molecular Markers in Leukemias and Lymphomas

Jerald P. Radich, Andrew D. Zelenetz, Wing C. Chan, Carlo M. Croce, Myron S. Czuczman, Harry P. Erba, Sandra J. Horning, Jane Houldsworth, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Meir Wetzler, and Jane N. Winter

– 4256 . 37 Press RD Galderisi C Yang R . A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response . Clin Cancer Res 2007 ; 13